Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Denbufylline in dementia: a double-blind controlled study.

T A Treves1, A D Korczyn

  • 1Department of Neurology, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel.

Dementia and Geriatric Cognitive Disorders
|November 24, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pseudo-anticipation in Creutzfeldt-Jakob disease is due to a rhomboid-shaped artifact.

European journal of neurology·2019
Same author

Clinical and radiological determinants of transient symptoms associated with infarction (TSI).

Journal of the neurological sciences·2018
Same author

High hair cortisol concentrations predict worse cognitive outcome after stroke: Results from the TABASCO prospective cohort study.

Psychoneuroendocrinology·2017
Same author

Gait instability in valproate-treated patients: Call to measure ammonia levels.

Acta neurologica Scandinavica·2017
Same author

Quality-of-life perception by Parkinson's disease patients and caregivers.

Acta neurologica Scandinavica·2017
Same author

The effect of schooling on reported age of onset of cognitive decline: A collaborative study.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia·2016
Same journal

Understanding Discrepancies and Predictors of Self- versus Proxy-Rated Quality of Life in Chinese Community-Dwelling Older Adults with Mild Dementia: A Cross-Sectional Study.

Dementia and geriatric cognitive disorders·2026
Same journal

An Investigation of the Psychometric Properties of the Farsi Version of the Saint Louis University Mental Status (SLUMS) Examination.

Dementia and geriatric cognitive disorders·2026
Same journal

Examining the decision to take a dementia risk test: Considerations for privacy in screening at-home.

Dementia and geriatric cognitive disorders·2026
Same journal

Caregiving Models and Cognitive Decline in Middle-aged and Older Adults with Limitations in Activities of Daily Living: A CHARLS Cohort Study (2011-2020).

Dementia and geriatric cognitive disorders·2026
Same journal

Utility of Fox and Reverse Fox Finger Imitation Tasks for Screening Cognitive Impairment in Older Adults: A Neuroimaging Study.

Dementia and geriatric cognitive disorders·2026
Same journal

Knowledge, attitude, and practice toward Alzheimer's disease prevention among middle-aged and elderly individuals: a cross-sectional study.

Dementia and geriatric cognitive disorders·2026
See all related articles

Denbufylline did not prove effective for treating cognitive dysfunction in vascular dementia or Alzheimer's disease. While some patients showed cognitive score improvements, these effects were not statistically significant, suggesting limited therapeutic benefit.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Geriatrics

Background:

  • Cognitive dysfunction significantly impacts patients with vascular dementia (VD) and dementia of the Alzheimer type (DAT).
  • Xanthine derivatives are explored for potential cognitive-enhancing properties.

Purpose of the Study:

  • To evaluate the efficacy of denbufylline in treating cognitive dysfunction in patients with VD and DAT.
  • To assess the safety and tolerability of denbufylline in these patient populations.

Main Methods:

  • A randomized, double-blind, placebo-controlled trial involving 336 patients (110 with VD, 226 with DAT).
  • Patients received denbufylline (25, 50, or 100 mg) or placebo twice daily for 16 weeks after a 4-week placebo run-in period.
  • Cognitive function was assessed using the Mini-Mental State Examination (MMSE) and the Digit Substitution Subtest (DSST) of the Wechsler Memory Scale.

Related Experiment Videos

Main Results:

  • No statistically significant differences in MMSE or DSST scores were observed between denbufylline and placebo groups at the study's end.
  • A trend towards improved MMSE scores was noted in the denbufylline group (67% improvement) compared to placebo (46% improvement), though not statistically significant (p < 0.05).
  • No dose-dependent effect of denbufylline was identified, and responses in VD and DAT patients were similar. A significant placebo effect was observed.

Conclusions:

  • Denbufylline was not found to be efficacious in treating cognitive dysfunction associated with DAT or VD.
  • While a tendency for cognitive improvement was observed with denbufylline, the lack of statistical significance limits its therapeutic potential.
  • The study highlights the notable placebo effect in dementia trials and the need for robust statistical power to detect modest treatment effects.